thank you rlbeard6734. I appreciate the feedback. I was very interested in PTX so I will do some more research. They seem to be well managed and could be my next HZNP which has paid off well.
This board is great. I am loaded on HZNP. Just sold a stock and looking to buy more and maybe something else. Don't want to offend anyone just wondering if anybody was following CRIS or PTX and if you had any input. Mike and PB had great information for HZNP that followed closely. Thank you.
This is frustrating. Who knows what is going on. Hopefully in the next few weeks the critics change their tune and the gamers keep playing. It still has plenty of potential.
somebody knows something we don't. It is being manipulated for sure.
Mike do you think there as any probably this over reacted just a little bit and might open up a little higher tomorrow or drop a few more points tomorrow?
This is really ridiculous. Who knows what will happen tomorrow. Strong beat on the numbers does not mean anything anymore.
That was funny. Some individuals can't hide being stupid or judgemental. They cannot take responsibility for their actions. Always appreciate your insight. I have never known it to be a bad thing to get multiple opinions especially when they have merit. thanks for your posts.
Thank you. Hope you let us know when you decide to buy back in. Like your timing and analysis and it is always good to get as many opinions as possible.
Hello mike like you posts. I was wondering what your re entry point is on HZNP is if you have one. Are waiting until after earnings or for a particular price or any other analysis that you are using?
Maybe you have heard of these companies and drugs below that TW managed to make money for. Maybe not but you need to do a little research or just read.
From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which is on track to exceed $10.0 billion in 2013 sales, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth.